Hengyu Mao1. 1. Department of Thoracic Surgery, Fudan University Shanghai Cancer Center, Shanghai 200032, China.
Abstract
BACKGROUND: Intra-tumor heterogeneity (ITH) plays an important role in the progressing of lung adenocarcinoma (LUAD). We used a mutant-allele tumor heterogeneity (MATH) algorithm to measure ITH and the correlation between ITH and clinical parameters and its prognosis. METHODS: We assessed 230 LUAD patients from The Cancer Genome Atlas (TCGA). We calculated the MATH values from whole-exome sequencing data and further investigated their correlation with clinical characteristics. RESULTS: The patients were divided into low and high MATH groups. People with high MATH were more likely to be female, smoking and EGFR mutation. And a high MATH may predict a poor prognosis. CONCLUSIONS: MATH is a new method for describing the internal heterogeneity of tumors in lung cancer. We used TCGA data to demonstrate that groups with higher MATH values are more likely to be female, smoker and EGFR mutations, and may have a poor prognosis. 2019 Annals of Translational Medicine. All rights reserved.
BACKGROUND: Intra-tumor heterogeneity (ITH) plays an important role in the progressing of lung adenocarcinoma (LUAD). We used a mutant-allele tumor heterogeneity (MATH) algorithm to measure ITH and the correlation between ITH and clinical parameters and its prognosis. METHODS: We assessed 230 LUAD patients from The Cancer Genome Atlas (TCGA). We calculated the MATH values from whole-exome sequencing data and further investigated their correlation with clinical characteristics. RESULTS: The patients were divided into low and high MATH groups. People with high MATH were more likely to be female, smoking and EGFR mutation. And a high MATH may predict a poor prognosis. CONCLUSIONS: MATH is a new method for describing the internal heterogeneity of tumors in lung cancer. We used TCGA data to demonstrate that groups with higher MATH values are more likely to be female, smoker and EGFR mutations, and may have a poor prognosis. 2019 Annals of Translational Medicine. All rights reserved.
Authors: Edmund A Mroz; Aaron D Tward; Curtis R Pickering; Jeffrey N Myers; Robert L Ferris; James W Rocco Journal: Cancer Date: 2013-05-20 Impact factor: 6.860
Authors: Marco Gerlinger; Andrew J Rowan; Stuart Horswell; James Larkin; David Endesfelder; Eva Gronroos; Pierre Martinez; Nicholas Matthews; Aengus Stewart; Charles Swanton; M Math; Patrick Tarpey; Ignacio Varela; Benjamin Phillimore; Sharmin Begum; Neil Q McDonald; Adam Butler; David Jones; Keiran Raine; Calli Latimer; Claudio R Santos; Mahrokh Nohadani; Aron C Eklund; Bradley Spencer-Dene; Graham Clark; Lisa Pickering; Gordon Stamp; Martin Gore; Zoltan Szallasi; Julian Downward; P Andrew Futreal Journal: N Engl J Med Date: 2012-03-08 Impact factor: 91.245
Authors: Scott L Carter; Kristian Cibulskis; Elena Helman; Aaron McKenna; Hui Shen; Travis Zack; Peter W Laird; Robert C Onofrio; Wendy Winckler; Barbara A Weir; Rameen Beroukhim; David Pellman; Douglas A Levine; Eric S Lander; Matthew Meyerson; Gad Getz Journal: Nat Biotechnol Date: 2012-05 Impact factor: 54.908
Authors: Stephanie J Yaung; Christine Ju; Sandeep Gattam; Alan Nicholas; Nicolas Sommer; Johanna C Bendell; Herbert I Hurwitz; John J Lee; Fergal Casey; Richard Price; John F Palma Journal: Cancers (Basel) Date: 2022-04-29 Impact factor: 6.575